COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a preliminary assessment from a case-control study in St. Petersburg, RussiaArticle Published on 2022-09-222022-11-16 Journal: BMC Public Health [Category] SARS, 변종, [키워드] adjusted age Analysis arising case-control study caused Computed tomography conducted Control country COVID-19 COVID-19 vaccine delta variant Delta VOC effective Effectiveness Final Gam-COVID-Vac LIGHT logistic regression model low-dose men mRNA outbreak PCR polymerase chain Prevalence primary analysis random recruited Russia SARS-CoV-2 SARS-COV-2 infection Sex symptomatic symptomatic infection symptomatic patient symptomatic SARS-CoV-2 infection Vaccine vaccine effectiveness Vaccines women [DOI] 10.1186/s12889-022-14202-9 PMC 바로가기
Genomic surveillance of SARS-CoV-2 Omicron variants on a university campusArticle Published on 2022-09-062022-11-15 Journal: Nature Communications [Category] SARS, 변종, 유전자 메커니즘, 진단, [키워드] conducted Cycle threshold value Delta delta variant demonstrated Genome genomic Genomic surveillance greater individual Mask mandates Measures median novel omicron pandemic positive predominant Public health responses reproductive SARS-CoV-2 sequenced Sequencing surveillance data symptomatic infection tested the SARS-CoV-2 university vaccination variant viral strain whole genome [DOI] 10.1038/s41467-022-32786-z PMC 바로가기
All-People-Test-Based Methods for COVID-19 Infectious Disease Dynamics Simulation Model: Towards Citywide COVID TestingArticle Published on 2022-09-022022-11-15 Journal: International Journal of Environmental Research an [Category] SARS, 치료기술, 치료제, [키워드] Asymptomatic case asymptomatic infection collected Community Contact tracing COVID COVID-19 COVID-19 pandemic COVID-19 sampling pooling cumulative death Defense described Dynamics Effect effective Epidemic evaluated experiment Follow-up help Hong Kong Infection Infectious disease information International Large-scale testing measure Mild symptom mobile app precise tracking technology parameter problem reduce reported required researcher Screening screening method SETPG (A + I) RD + APT model Simulation Spread symptomatic infection tested Testing the epidemic the United State timespan Total Transmission Transmission dynamics variable virus [DOI] 10.3390/ijerph191710959 PMC 바로가기
Infection with SARS-CoV-2 Omicron Variant 24 Days after Non-Omicron Infection, Pennsylvania, USAArticle Published on 2022-09-012022-11-16 Journal: Emerging Infectious Diseases [Category] SARS, 변종, [키워드] acute respiratory syndrome coronavirus coronavirus disease COVID-19 COVID-19 vaccination Day first positive omicron Pennsylvania respiratory infections SARS-CoV-2 SARS-CoV-2 test severe acute respiratory syndrome coronavirus 2 suggested symptomatic infection symptomatic SARS-CoV-2 infection United States USA vaccine-preventable diseases variant viruses whole-genome sequencing zoonoses [DOI] 10.3201/eid2809.220539 PMC 바로가기
Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe OutcomesArticle Published on 2022-09-012022-11-16 Journal: JAMA Network Open [Category] SARS, 변종, [키워드] 95% CI administration Against age calculated Canada case-control study Control COVID-19 COVID-19 symptom COVID-19 vaccination COVID-19 vaccine database death Delta delta variant disease dose Effectiveness Estimated female Health Hospitalization incidence individual Infection infections Laboratory testing Logistic regression Older omicron outcome outcomes participant Participants Preventing receipt SARS-CoV-2 SARS-COV-2 infection second dose symptomatic symptomatic infection tested understanding vaccination Vaccine Vaccines variant variants was used [DOI] 10.1001/jamanetworkopen.2022.32760 PMC 바로가기
SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic InfectionArticle Published on 2022-08-312022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] anti-SARS-CoV-2 anti-SARS-CoV-2 antibody antibodies antibody antibody concentration Antigen benefit binding antibody booster dose circulating collected Concentration Correlate of protection correlated correlation COVID-19 COVID-19 vaccine detectable detectable anti-SARS-CoV-2 antibodies Efficacy estimate Evidence exceeded Guidance IgG immune Immunity include Infection Neutralizing Neutralizing antibodies new SARS-CoV-2 observation Postinfection postvaccination Prevent proportion protection Protective provide public health Quantitative recommendation SARS-CoV-2 SARS-COV-2 infection serum specimen standardized. study population Support symptomatic symptomatic infection vaccination variant virus strains with COVID-19 [DOI] 10.1128/spectrum.01247-22 PMC 바로가기
Investigation of a Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) Variant Outbreak Among Residents of a Skilled Nursing Facility and Vaccine Effectiveness Analysis: Maricopa County, Arizona, June-July 2021중증 급성 호흡기 증후군 코로나바이러스 2 델타(B.1.617.2) 전문 요양 시설 거주자의 변종 발병 및 백신 효과 분석: 2021년 6월-7월 애리조나주 마리코파 카운티에 대한 조사Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted affected assistance B.1.617.2 calculated clinical outcomes complex coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 Coverage COVID-19 Cox proportional hazard Cox proportional hazards models Delta delta variant demographics Department died dose Effectiveness electronic medical record estimate facility health department highest Hospitalized Immunocompromised inclusion criteria infection control investigation Local local public health male median age Medical conditions Messenger RNA mRNA mRNA vaccine Nursing outbreak Outbreaks outcomes positive Public public health rehabilitation resident respiratory SARS-CoV-2 SARS-CoV-2 test severe acute respiratory syndrome Coronavirus skilled nursing facility symptomatic infection tested unique vaccination vaccination rate Vaccination Status Vaccine white [DOI] 10.1093/cid/ciac240 PMC 바로가기 [Article Type] Article
Antibodies in the breastmilk of COVID-19 recovered women코로나19 회복된 여성의 모유에 있는 항체Article Published on 2022-08-112022-09-11 Journal: BMC Pregnancy and Childbirth [Category] SARS, 진단, 치료기술, [키워드] acute respiratory syndrome coronavirus anti-RBD IgA anti-SARS-CoV-2 IgG antibodies antibody antibody levels Asymptomatic benefit Breast breast milk Breastfeeding breastmilk characterized clinical symptom Clinical symptoms collected Concentration control group coronavirus coronavirus 2 COVID-19 COVID-19 disease enzyme enzyme-linked immunosorbent assay Human human milk IgA IgG IgG antibodies IgG antibody immunization immunoglobulins Immunoglobulins, passive immunity Infant Infants lactating mother no statistically significant difference passive immunity passive immunization positive protective factor RBD IgA respiratory SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 test serum serum sample serum samples severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severity statistically significant difference symptomatic and asymptomatic symptomatic infection test result virus transmission was performed with COVID-19 women [DOI] 10.1186/s12884-022-04945-z PMC 바로가기 [Article Type] Article
Inactivated vaccine Covaxin/BBV152: A systematic review비활성화 백신 Covaxin/BBV152: 체계적인 검토Article Published on 2022-08-092022-09-11 Journal: Frontiers in Immunology [Category] SARS, 변종, [키워드] adjusted Administered adverse event Aluminium aluminium hydroxide Antigen AZD1222 BBV152 Beta Bharat binding antibody clinical trial Combination Corona Covaxin Coverage Covishield Delta Delta variants doses Effectiveness Efficacy Evidence evidence of fatality gel heterologous prime-boost hydroxide immunogenicity inactivated Inactivated vaccine India infected individual Local Neutralizing omicron Omicron variant pandemic phase Phase I Phase III trials provided Quinolin reported Safety safety profile SARS-CoV-2 pandemic screened searched second dose Serious Adverse Event Serious Adverse Events severe COVID-19 surpassed symptomatic infection systematic review systemic adverse events T cell T cell response T cell responses the SARS-CoV-2 Trial vaccination Vaccine Vaccines variant variants virus Zeneca [DOI] 10.3389/fimmu.2022.863162 PMC 바로가기 [Article Type] Article
Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study항바이러스제를 광범위하게 사용하면 COVID-19 전염병을 억제할 수 있습니까? 모델링 연구Article Published on 2022-08-092022-09-11 Journal: BMC Infectious Diseases [Category] SARS, 치료제, [키워드] age agent agent-based model analyzed Antiviral antiviral drug antiviral drugs Antiviral effect antiviral effects Antiviral treatment antiviral treatments Belgium Combination country COVID-19 COVID-19 disease COVID-19 hospitalization death deaths disease effective Effective vaccines help highlight Hospitalization inception Increases Infection Kenya location majority mathematical mathematical model mitigate Mortality Older populations Prevent prevented progression reduce reduced reducing Safe SARS-CoV-2 SARS-CoV-2 transmission shown significantly symptomatic symptomatic infection symptoms onset synergistic synergistic effect Transmission Treatment treatment initiation treatments for COVID-19 United State United States vaccination vaccination rate widespread [DOI] 10.1186/s12879-022-07639-1 PMC 바로가기 [Article Type] Article